FDA reviewer recommends against Pfizer drug
from The Wall Street Journal
A Food and Drug Administration medical reviewer recommended the agency not approve a drug developed by a Pfizer subsidiary to treat a rare genetic disorder that affects the nervous system because there's "inadequate" evidence the drug works. Pfizer subsidiary FoldRx is seeking FDA approval of a drug called tafamidis to treat an inherited condition called transthyretin familial amyloid polyneuropathy.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063